June is men’s health month. You’ve probably been reminded to ‘get your PSA checked.’ but you may not have heard of a PSMA ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

PSMA PET imaging for evaluation of recurrent or persistent prostate cancer after primary prostate radiation. Differences between whole body magnetic resonance imaging (WB-MRI) and chest/abdomen/pelvis ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

New PSMA PET/CT can detect signs of prostate cancer within elderly patients without the need of a biopsy. PSMA PET/CT scans can detect signs of prostate cancer in elderly patients without the need of ...

Source: Getty Images The molecular imaging modality detects metastases earlier and more accurately compared with conventional imaging and has ushered in a new era in metastasis-directed therapy. PSMA ...

Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA. Prostate specific antigen (PSA) is a ...

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

The partners will incorporate Telix's PSMA-PET gallium 68-based imaging agents Gozellix and Illuccix with EDAP and Profound's technologies for minimally invasive treatment.

An interview with Dr. Rohan Garje from Miami Cancer Institute in Miami, FL, lead author on "Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO ...